

Libocare Medical Trade Private Limited
 CIN - U51909UP2021PTC152609
 BALANCE SHEET AS AT 31 MARCH, 2025
 (All amount in Rupees Thousands, unless otherwise stated)

	Note No.	As at 31 March, 2025 (Rupees)	As at 31 March, 2024 (Rupees)
A. EQUITY AND LIABILITIES			
1. SHAREHOLDERS' FUNDS			
a. Share capital	3.	1,000.00	1,000.00
b. Reserves and surplus	4.	(326.62)	(1823.68)
		<u>673.38</u>	<u>176.32</u>
2. CURRENT LIABILITIES			
a. Trade payables	5.	-	-
- Total outstanding dues of micro enterprises and small enterprises	5.	1,989.36	76.51
- Total outstanding dues of creditors other than micro enterprises and small enterprises	5.	618.59	59.44
b. Other current liabilities	6.	2,607.95	135.95
	TOTAL	<u>3,281.33</u>	<u>312.27</u>
B. ASSETS			
3. CURRENT ASSETS			
a. Cash and cash equivalents	7.	357.77	142.00
b. Trade receivables	8.	1,031.31	-
c. Short-term loans and advances	9.	1,892.25	170.27
	TOTAL	<u>3,281.33</u>	<u>312.27</u>

See accompanying notes forming part of the financial statements

1 - 30

In terms of our report attached

For JGAD & Associates
 Chartered Accountants
 FRN No - 0290401N

CA SATIN GUPTA
 Partner
 M. No. 522225
 UDIN: 25522225BMKQDUI613

Place : New Delhi
 Date: Sep 29, 2025

For and on behalf of the Board of Director
 Libocare Medical Trade Private Limited

Aggarwal
 Garvit Aggarwal
 Director
 DIN:08593294

Simon Mitterer
 Director
 DIN:09329653

Place : Tirol, Austria
 Date: Sep 29, 2025

Place : Gurugram
 Date: Sep 29, 2025

Libocare Medical Trade Private Limited
 CIN :- US1909UP2021PTC152609
 STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED 31 MARCH, 2025
 (All amount in Rupees Thousands, unless otherwise stated)

	Note No.	Year ended 31 March, 2025	Year ended 31 March, 2024
1. INCOME			
a. Revenue from operations			
TOTAL INCOME	10.	5,708.07	-
2. EXPENSES			
a. Employee benefits expense	11.	634.13	-
b. Finance costs	12.	20.46	21.83
c. Other expenses	13.	4,382.37	631.85
TOTAL EXPENSES		5,036.96	653.68
3. Profit / (Loss) before tax (1-2)		671.11	(653.68)
4. Tax Expense:			
a. Current Tax		174.05	-
		174.05	-
5. Profit / (Loss) for the year		497.06	(653.68)
6. PROFIT PER SHARE			
Basic/ Dilutive Earnings per share (Nominal value per share Rupees 10)	23.	4.97	(6.54)

See accompanying notes forming part of the financial statements

1 - 30

In terms of our report of even date attached

For JCAD & Associates
 Chartered Accountants
 FRN No - 0290401N

Jatin
 CA JATIN GUPTA
 Partner
 M. No. 522225
 UDIN: 2552225RMKQDU1613

Place : New Delhi
 Date: Sep 29, 2025

For and on behalf of the Board of Director
 Libocare Medical Trade Private Limited

Garvit Aggarwal
 Simon Mitterer
 Director
 DIN:09329653
 Garvit Aggarwal
 Director
 DIN:08593294

Place : Tirol, Austria
 Date: Sep 29, 2025

Place : Gurugram
 Date: Sep 29, 2025

Libocare Medical Trade Private Limited
 CIN :- U51909UP2021PTC152609
 Cash Flow Statement for the year ended 31 March, 2025
 (All amount in Rupees Thousands, unless otherwise stated)

	Year ended 31 March, 2025	Year ended 31 March, 2024
A. Cash Flow from operating activities:		
Profit before tax	671.11	(653.68)
Adjustments for:		
Depreciation	-	-
Operating profit before working capital changes	671.11	(653.68)
Changes in working capital:		
Increase/ (Decrease) in trade payables	1,912.85	(76.50)
Increase/(Decrease) in other current liabilities	559.15	42.45
Decrease/(Increase) in trade receivables	(1,031.31)	-
Decrease/(Increase) in short term loans & advances	(1,624.03)	(170.27)
Cash generated from operations	487.77	(858.00)
Income tax paid	(272.00)	-
Net Cash from/ (used in) operating activities (A)	215.77	(858.00)
B. Cash Flow from investing activities:	-	-
C. Cash Flow from financing activities:	-	1,000.00
Net Increase in Cash & Cash Equivalents (A+B+C)	215.77	142.00
Cash and cash equivalents at the beginning of the year	142.00	-
Cash and Cash Equivalents as at end of the year	357.77	142.00
Cash & Cash Equivalents comprise (refer note 7):	357.77	142.00

See accompanying notes forming part of the financial statements

1 - 30


In terms of our report of even date attached

For JGAD & Associates
 Chartered Accountants
 FRN No - 0290401N


 CA JATIN GUPTA
 Partner
 M. No. 52225
 UDIN: 25522225BMKQDU1613

Place : New Delhi
 Date: Sep 29, 2025

For and on behalf of the Board of Director
 Libocare Medical Trade Private Limited


 Simon Mitterer
 Director
 DIN:09329653

Garvit Aggarwal
 Director
 DIN:08593294

Place : Tirol, Austria
 Date: Sep 29, 2025

Place : Gurugram
 Date: Sep 29, 2025

Libocare Medical Trade Private Limited**Notes to Financial Statements for the year ended 31st March 2025****1. Corporate Information**

Libocare Medical Trade Private Limited (the Company) is a private limited company domiciled in India and incorporated under the Companies Act, 2013 on 22nd September 2021. The Company is operating under only one business segment i.e. trading in medical equipments.

2. Basis of Preparation

The financial statements of the company have been prepared in accordance with the generally accepted accounting principles in India (Indian GAAP). The company has prepared these financial statements to comply in all material respects with the accounting standards notified under section 133 of the Companies Act 2013, read together with the Companies (Accounting Standards) Amendment Rules, 2021 (amended). The financial statements have been prepared on an accrual basis and under the historical cost convention. The accounting policies have been consistently applied by the Company.

All assets and liabilities have been classified as current or non-current as per the Company's operating cycle and other criteria set out in the Schedule III (Division I) to the Companies Act, 2013. Based on the nature of services rendered by the company and the time between the acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current and non current classification of assets and liabilities.

2.1 Summary of significant accounting policies**a) Use of Estimates**

The preparation of financial statements in conformity with Indian GAAP requires the management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities and the disclosure of contingent liabilities, at the end of the reporting period. Although these estimates are based on the management's best knowledge of current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

b) Property, Plant & Equipment

There are no fixed assets during the year ended March 31, 2025

c) Revenue Recognition

Revenue from sale of service is recognised as per terms of agreement with group company. It is recognised when such services are rendered. Revenue is determined by applying agreed markup to the cost incurred in rendering such services as agreed in the agreement with the group company

d) Earnings per Share

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. The weighted average numbers of equity shares are adjusted for events such as bonus issue, bonus element in the rights issue, share split and reverse share split (consolidation of shares) that have changed the number of equity shares outstanding, without corresponding change in resources.

For the purpose of calculating diluted earnings per share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

e) Contingent liabilities

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The company does not recognize a contingent liability but discloses its existence in the financial statements.

f) Provisions

A provision is recognized when the Company has a present obligation as a result of past event, the settlement of which is expected to result in an outflow of resources embodying economic benefits and reliable estimate can be made of the amount of the obligation. Provisions are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the reporting date. These estimates are reviewed at each Balance Sheet date and adjusted to reflect the current best estimate.

Where the Company expects some or all of a provision to be reimbursed, for example under an insurance contract, the reimbursement is recognized as a separate asset but only when the reimbursement is virtually certain. The expense relating to any provision is presented in the statement of profit and loss net of any reimbursement.

g) Cash and cash equivalents

Cash and cash equivalents for the purposes of cash flow statement comprise cash at bank and in hand and short-term investments with an original maturity of twelve months or less.

h) Foreign currency transactions

Initial recognition

Transactions in foreign currencies entered into by the Company are accounted at the exchange rates prevailing on the date of the transaction or at rates that closely approximate the rate at the date of the transaction.

Measurement of foreign currency monetary items at the Balance Sheet date.

Foreign currency monetary items of the Company outstanding at the Balance sheet date are restated at the period-end rates.

Treatment of exchange differences

Exchange differences arising on settlement / restatement of short-term foreign currency monetary assets and liabilities of the Company are recognized as income or expense in the Statement of Profit and Loss.

i) Current and Deferred Tax

Tax expense for the year comprising current and deferred tax is included in determining the net profit for the year.

Current tax

Provision for current tax comprises of current income tax and is made after taking into consideration benefits admissible under the provisions of the Income Tax Act, 1961. Income taxes are accrued in the same period the related revenue and expenses arise.

Deferred tax

Provision for deferred tax (reflecting the tax effects of timing differences between accounting income & taxable income for the period) is determined in accordance with Accounting Standard-22 issued by Ministry of Corporate Affairs. The deferred tax charge or credit and the corresponding deferred tax liabilities or assets are recognized using the tax rates that have been enacted or substantially enacted by the balance sheet date.

Libocare Medical Trade Private Limited**Notes to financial statements for the year ended March 31, 2025****(All amount in Rupees Thousands, unless otherwise stated)**

	As at 31 March, 2025	As at 31 March, 2025
3. SHARE CAPITAL.		
(a) Authorized Shares 100,000 (100,000 as at 31 March, 2024) equity shares of Rs. 10 each	1,000.00	1,000.00
(b) Issued, subscribed and fully paid up : 100,000 (100,000 as at 31 March, 2024) equity shares of Rs. 10 each	1,000.00	1,000.00

See notes (i) to (iv) below

(i) The Company has issued only one class of equity shares having par value of Rs. 10 per share. Each shareholder is entitled to one vote per share. The dividend if proposed by the Board of Directors is subject to approval of the shareholders in the ensuing Annual General Meeting, except in case of interim dividend. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.

(ii) **Reconciliation of the number of equity shares outstanding at the beginning and at the end of the reporting period:**

Particulars	Year Ended 31 March, 2025		Year Ended 31 March, 2024	
	No. of Shares	Amount (Rupees)	No. of Shares	Amount (Rupees)
Equity shares				
At the beginning of the period	1,00,000	1,000.00	1,00,000	1,000.00
Add: Shares issued during the period	-	-	-	-
At the end of the period	1,00,000	1,000.00	1,00,000	1,000.00

(iii) **Details of shares held by each shareholder holding more than 5% shares:**

Particulars	Year Ended 31 March, 2025		Year Ended 31 March, 2024	
	No. of Shares	% Holding	No. of Shares	% Holding
Equity shares with voting rights (fully paid up)				
Mr. Simon Mitterer	99999	99.99%	99999	99.99%

(iv) **Details of Shares held by promoters at the end of the year:**

Promoter's Name	Year Ended 31 March, 2025		Change during year	Year Ended 31 March, 2024	
	No. of Shares	% Holding		No. of Shares	% Holding
Mr. Simon Mitterer	99999	99.99%	-	99999	99.99%
Mr. Garvit Aggarwal (As Nominee of Mr. Simon Mitterer)	1	0.01%	-	1	0.01%
	100000	100%	-	100000	100%

Libocare Medical Trade Private Limited
 Notes to financial statements for the year ended March 31, 2025
 (All amount in Rupees 'Thousands, unless otherwise stated)

	As at 31 March, 2025 (Rupees)	As at 31 March, 2025 (Rupees)
4. RESERVES AND SURPLUS		
a. Statement of profit and loss account		
i. Opening balance	(823.68)	(170.00)
ii. Add : Profit /(Loss) for the year	497.06	(653.68)
iii. Closing balance	<u>(326.62)</u>	<u>(823.68)</u>
5. TRADE PAYABLES (refer note 20)		
a. Trade Payables		
- Total outstanding dues to micro enterprises and small enterprises (Refer note 22)	-	-
- Total outstanding dues to creditors other than micro enterprises and small enterprises	<u>1,989.36</u>	<u>76.51</u>
	<u>1,989.36</u>	<u>76.51</u>
6. OTHER CURRENT LIABILITIES		
a. Other Payables		
i. Unearned revenue (refer note 16)	371.88	-
ii. Statutory remittances	233.53	59.44
iii. Interest on income tax payable	<u>13.18</u>	<u>-</u>
	<u>618.59</u>	<u>59.44</u>
7. CASH AND CASH EQUIVALENTS		
a. Balance with bank:		
In current account	<u>357.77</u>	<u>142.00</u>
	<u>357.77</u>	<u>142.00</u>
8. TRADE RECEIVABLES (Unsecured, considered good) (refer note 21)		
a. Outstanding for a period exceeding 6 months from the date they are due for payment	-	-
b. Others (refer note 16)	<u>1,031.31</u>	<u>-</u>
	<u>1,031.31</u>	<u>-</u>
9. SHORT-TERM LOANS AND ADVANCES (Unsecured, considered good)		
a. Receivables from the related party (refer note 16)	1,262.56	-
b. Advance to vendors other than capital advances	26.16	159.79
c. Prepaid Expenses	53.71	10.48
d. Balances with government authorities		
- GST receivables including deferred GST	451.87	-
- Advance tax (net of provision for taxation)	<u>97.95</u>	<u>-</u>
	<u>1,892.25</u>	<u>170.27</u>

Libocare Medical Trade Private Limited

Notes to financial statements for the year ended March 31, 2025

(All amount in Rupees Thousands, unless otherwise stated)

	Year ended 31 March, 2025 (Rupees)	Year ended 31 March, 2024 (Rupees)
10. REVENUE FROM OPERATIONS		
a. Sale of services (refer note 16)	5,708.07	-
	<u>5,708.07</u>	<u>-</u>
11. EMPLOYEE BENEFITS EXPENSE		
a. Salaries, bonus and wages	619.69	-
b. Staff welfare expenses	14.44	-
	<u>634.13</u>	<u>-</u>
12. FINANCE COSTS		
a. Other interest	20.46	21.83
- Delayed payment of income tax	<u>20.46</u>	<u>21.83</u>
13. OTHER EXPENSES		
a. Legal and professional charges (Refer below note)	4,270.18	625.04
b. Subscription charges	41.55	5.82
c. Miscellaneous expenses	27.09	-
d. Communication expenses	24.76	-
e. Loss on foreign currency transaction and translations (net)	9.44	-
f. Travelling and conveyance	5.29	-
g. Rates and taxes	3.00	-
h. Bank charges	1.06	0.99
	<u>4,382.37</u>	<u>631.85</u>
Notes:		
Auditor's fee (excluding indirect taxes) as follows:		
a. Statutory audit fees	85.00	85.00
b. Out of pocket expenses	<u>85.00</u>	<u>85.00</u>

Libocare Medical Trade Private Limited

Notes to financial statements for the year ended March 31, 2025
 (All amount in Rupees Thousands, unless otherwise stated)

14. COMMITMENT

The Company does not have other commitments, for purchases/sales orders which are issued after considering requirements per operating cycle for purchase/sale of services and employees benefits, in normal course of business. The Company does not have any long term commitments/contracts including derivative contracts for which there will be any material foreseeable losses.

There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
 The Company does not have any pending litigations which would impact its financial position.

15. OPERATING LEASES: Company as lessee

The Company has not entered into any operating lease arrangements for any facilities and office premises.

16. RELATED PARTY DISCLOSURE**I. List of related parties**

i Fellow Subsidiary	Metron Handel GmbH
ii Key management personnel (KMP)	Mr. Simon Mitterer
iii Shareholders	Mr. Garvit Aggarwal (as nominee of Mr. Simon Mitterer)

II. Transactions with related parties :

Particulars	Fellow Subsidiary Company	Key Managerial Personnel	Shareholders	Total
i. Receipt of share application money Mr. Simon Mitterer	-	(1,000.00)	-	(1,000.00)
ii. Sale of Services Metron Handel GmbH	5,708.07 (-)	- (-)	- (-)	5,708.07 (-)
iii. Expenditures incurred on behalf of Mr. Simon Mitterer	-	1,262.56 (-)	- (-)	1,262.56 (-)

III. Outstanding balances at year-end:

Particulars	Fellow Subsidiary Company	Key Managerial Personnel	Shareholders	Total
i. Share Capital Mr. Simon Mitterer	- (-)	999.99 (999.99)	- (-)	999.99 (999.99)
Mr. Garvit Aggarwal (as Nominee)	- (-)	- (-)	0.01 (0.01)	0.01 (0.01)
ii. Trade receivables Metron Handel GmbH	1,031.31 (-)	- (-)	- (-)	1,031.31 (-)
iii. Receivables from the related party Mr. Simon Mitterer	- (-)	1,262.56 (-)	- (-)	1,262.56 (-)
iv. Unearned revenue Metron Handel GmbH	371.88 (-)	- (-)	- (-)	371.88 (-)

Note: Figures in brackets relate to previous year.

Libocare Medical Trade Private Limited
 Notes to financial statements for the year ended March 31, 2025
 (All amount in Rupees Thousands, unless otherwise stated)

17. EARNING IN FOREIGN CURRENCY

Particulars	Year ended 31 March, 2025	Year ended 31 March, 2024
Sale of services	5,708.07	

18. DETAILS OF UNHEDGED FOREIGN CURRENCY EXPOSURES

Particulars	Currency	Year ended 31 March, 2025	Year ended 31 March, 2024
Trade receivable	EURO Equivalent Rupees	11.14 1,031.31	-

19. TRANSFER PRICING

The Company is in the process of establishing a comprehensive system of maintenance of information and documents as required by the transfer pricing legislation under sections 92-92F of the Income Tax Act, 1961 for its international transactions. Since the law requires such information and documentation to be contemporaneous in nature, the Company is in the process of updating the documentation for the transactions with the associated enterprises during the financial year and expects such records to be in existence as per the provision of relevant tax law. The management is of the opinion that all above transactions are at arm's length so that the aforesaid legislation will not have any impact on the financial statements.

20. Trade Payables ageing schedule

Particulars Year ended 31 March 2025	Outstanding for following periods from due date of payment/transaction					Total
	Not Due	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	
(i) Undisputed trade payables - MSME	-					-
- Others	-	1,989.36				1,989.36
(ii) Disputed trade payables - MSME	-					-
- Others	-					-

Particulars Year ended 31 March 2024	Outstanding for following periods from due date of payment/transaction					Total
	Not Due	Less than 1 year	1 - 2 years	2 - 3 years	More than 3 years	
(i) Undisputed trade payables - MSME	-					-
- Others	76.51	-				76.51
(ii) Disputed trade payables - MSME	-					-
- Others	-					-

Libcare Medical Trade Private Limited
Notes to financial statements for the year ended March 31, 2025
(All amount in Rupees Thousands, unless otherwise stated)

21. Trade Receivables ageing schedule

Particulars Year ended 31 March 2025	Not Due	Outstanding for following periods from due date of payment/transaction					Total
		Less than 6 months	6 months - 1 year	1 - 2 years	2 - 3 years	More than 3 years	
(i) Undisputed trade receivables							
- considered good	-	1,031.31	-	-	-	-	1,031.31
- considered doubtful	-	-	-	-	-	-	-
(ii) Disputed trade receivables							
- considered good	-	-	-	-	-	-	-
- considered doubtful	-	-	-	-	-	-	-

Particulars Year ended 31 March 2024	Not Due	Outstanding for following periods from due date of payment/transaction					Total
		Less than 6 months	6 months - 1 year	1 - 2 years	2 - 3 years	More than 3 years	
(i) Undisputed trade receivables							
- considered good	-	-	-	-	-	-	-
- considered doubtful	-	-	-	-	-	-	-
(ii) Disputed trade receivables							
- considered good	-	-	-	-	-	-	-
- considered doubtful	-	-	-	-	-	-	-

22. Disclosures required under Section 22 of the Micro, Small and Medium Enterprises Development Act, 2006

Particulars	Year ended 31 March, 2025	Year ended 31 March, 2024
a. Principal amount due to micro and small enterprises	-	-
b. Interest due on above	-	-
c. The amount of interest paid by the buyer in terms of section 16 of the MSED Act, 2006 along with the amounts of the payment made to the	-	-
d. The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually	-	-
e. The amount of interest accrued and remaining unpaid at the end of each accounting year	-	-
f. The amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually	-	-

Dues to Micro and Small enterprises as defined in section 7(1) of the Micro, Small and Medium Enterprises Development Act, 2006 to the extent such parties have been identified from the available information. This has been relied upon by auditors.

23. EARNINGS PER SHARE

Particulars	Unit	Year ended 31 March, 2025	Year ended 31 March, 2024
<u>Basic/Diluted</u>			
Net Profit after tax attributable to equity shareholders	Rupees	497.06	(653.68)
Weighted average number of equity shares outstanding during the period	Numbers	1,00,000	1,00,000
Nominal value per Equity Share	Rupees	10	10
Basic/ Dilutive Earning per share #	Rupees	4.97	-6.54

#The company doesn't have any outstanding Dilutive Equity Shares.

24. The Company has carried out its tax computation in accordance with the mandatory standard on accounting, Accounting Standard 22 - 'Accounting for Taxes on Income' issued under the Companies (Accounting Standard) Rules, 2006. The major components of deferred tax assets as recognised in the financial statements are as follows :

The company doesn't have any assets or liabilities on which deferred assets or liabilities are required to be created. Considering the same, the company doesn't provided any credit or expense on account of deferred tax.

25. Other Statutory Information

- (i) The Company do not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.
- (ii) The Company do not have any transactions with companies struck off.
- (iii) The Company do not have any charges or satisfaction which is yet to be registered with ROC beyond the statutory period.
- (iv) The Company have not traded or invested in Crypto currency or Virtual Currency during the financial year.
- (v) The Company have not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:
 - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
 - (b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries
- (vi) The Company have not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:
 - (a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
 - (b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries,
- (vii) The Group have not any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961)
- (viii) The company is not in contravention with the number of layers prescribed under section 2(87) of the Act.
- (ix) The company has not been declared wilful defaulter by any bank or financial institution or other lender
- (x) The Company has not entered into any Scheme of Arrangements that has been approved by the Competent Authority in terms of sections 230 to 237 of the Act.

26. The first AGM of the Company held on 25th September, 2023 for the adoption of annual accounts for the financial year starting from 22nd September, 2021 (since incorporation) to 31st March, 2022 by the shareholders of the company was held beyond the prescribed timelines under the Companies Act, 2013 which is subject to compounding by the concerned authority. The company is under the process of compounding for non-compliance under Section 441 for not conducting the AGM within the prescribed time limit under the Companies Act, 2013.

27. As per the provisions of Section 10A of the Companies Act, 2013, the Company was required to file Form INC-20A with the Registrar of Companies within a period of 180 days from the date of incorporation declaring that every subscriber to the memorandum has paid the value of the shares agreed to be taken by him. However, the Company received a full amount of subscription money on 14th June, 2023, i.e. after 180 days from incorporation. Therefore, the company has to apply for compounding for non-compliance with the provisions of Section 10A of the Companies Act, 2013.

Libocare Medical Trade Private Limited
 Notes to financial statements for the year ended March 31, 2025
 (All amount in Rupees Thousands, unless otherwise stated)

28. Ratio Analysis and its elements Operating ratios

Sr. No.	Ratios	Numerator	Denominator	31-Mar-25	31-Mar-24	% change
1	Current Ratio	Current assets	Current liabilities	1.26	2.30	-45%
2	Debt-Equity Ratio	Total debt	Shareholder's funds	Not Applicable	Not Applicable	Not Applicable
3	Debt Service Coverage Ratio	Earnings for debt service - Net profit after taxes + Non-cash operating expenses	Debt service = Interest & Lease Payments + Principal Repayments	Not Applicable	Not Applicable	Not Applicable
4	Return on Equity Ratio	Net Profits after taxes	Average shareholder's fund	0.74	-3.71	-120%
5	Inventory turnover ratio	Cost of Goods Sold or Sales	Average inventory	Not Applicable	Not Applicable	Not Applicable
6	Trade Receivables turnover ratio	Net Credit Sales - Revenue from operations	Average trade receivables	5.53	Not Applicable	553%
7	Trade Payables turnover ratio	Other expenses	Average trade payables	2.29	8.26	-73%
8	Net capital turnover ratio	Net sales - Revenue from operations	Average working capital = Current assets - Current liabilities	13.44	Not Applicable	1344%
9	Net profit ratio	Net profit after tax	Net sales = Revenue from operations	0.09	Not Applicable	9%
10	Return on capital employed (%)	Earnings before interest and taxes	Capital Employed = Tangible Net Worth (Total equity + Intangibles assets) + Total Borrowings + Deferred Tax Asset	1.00	-3.71	-127%
11	Return on investment	Interest income on deposits	Average investment during the year	Not Applicable	Not Applicable	Not Applicable

Reasons for change more than 25%:

1. During the year, company has started its operation. Considering the same, liabilities of the company has been increased and the referred ratio of the company declined as compared to last year.
2. During the year, company has started its operation. Considering the same, the referred ratio of the company is improved.
3. During the year, company has started its operation. Considering the same, the referred ratio of the company is surged.
4. During the year, company has pay out its liabilities out of fund received from its operation. Considering the same, the referred ratio of the company is improved.
5. During the year, company has started its operation. Considering the same, the referred ratio of the company is improved.
6. During the year, company has started its operation. Considering the same, the referred ratio of the company is improved.
7. During the year, company has started its operation. Considering the same, the referred ratio of the company is improved.
8. During the year, company has started its operation. Considering the same, the referred ratio of the company is improved.
9. During the year, company has started its operation. Considering the same, the referred ratio of the company is improved.

10. During the year, company has started its operation. Considering the same, the referred ratio of the company is improved.
29. Ministry of Corporate Affairs (MCA) vide its notification number G.S.R. 206(E) dated March 24, 2021 (extended from time to time) in reference to the proviso to Rule 3 (1) of the Companies (Accounts) Amendment Rules, 2021, introduced the requirement of only using such accounting software w.e.f April 01, 2023 which has a feature of recording audit trail of each and every transaction, creating an edit log of each change made in the books of accounts along with the date when such changes were made and ensuring that the audit trail cannot be disabled. The Institute of Chartered Accountants of India ("ICAI") issued an "Implementation guide on reporting on audit trail under rule 11(1) of the Companies (Audit and Auditors) Rules, 2014 (Revised 2024 edition)" in February 2024 relating to feature of recording audit trail. The Company has used accounting software for maintaining its books of account for the year ended March 31, 2025 which has a feature of recording audit trail (edit log) facility and the same has operated for all relevant transactions recorded in the software.

30. Previous year figures have been regrouped / reclassified, where necessary, to conform to this year's classification.

In terms of our report of even date attached

For JGAD & Associates
 Chartered Accountants
 PRN No: 02904019
 CA Jatin Gupta
 Partner
 M. No: 522225
 UDIN: 25522225BMRQDU673

Place : New Delhi
 Date: Sep 29, 2025

For and on behalf of the Board of Director
 Libocare Medical Trade Private Limited

Simon Mitterer
 Director
 DIN: 09329453

Garevital Agarwal
 Director
 DIN: 03593294

Place : Tiro, Austria
 Date: Sep 29, 2025

Place : Gurugram
 Date: Sep 29, 2025